- Working with COVID-19 Virus – An Update
- Queen’s-led research wins highly commended award at major UK data conference
- Sequencing of SARS-CoV2 – Uncovering an ever-changing virus
- Queen’s awarded funding to conduct COVID-19 rapid testing trial
- New study to identify highest risk factors for COVID-19
- Researchers highlight the impact of COVID-19 pandemic on patients with cancer
- National clinical trial to treat hospitalised patients with COVID-19
- Queen’s leading cell therapy clinical trial to help improve outcomes in COVID-19 patients
- New research alliance to seek new therapeutic and diagnostic approaches
- Working to find a treatment through drug screening
- Innovative research to fight respiratory disease
Queen’s awarded funding to conduct COVID-19 rapid testing trial
Queen’s University Belfast has received funding to conduct a trial with the aim of developing a rapid diagnostic test for COVID-19.
The study is in partnership with HiberGene Diagnostics Ltd, Medcaptain in China, and Italian Hospital IRCCS Ospedale Policlinico San Martino, who along with Queen’s, has been awarded €930,000 from EU H2020 to develop a highly accurate diagnostic test for COVID-19 that aims to show results within an hour.
The test would enable clinicians to test for COVID-19 on site, eliminating the need to send tests to a centralised laboratory, saving time and resources.
Professor Cliff Taggart, lead researcher from the Wellcome-Wolfson Institute for Experimental Medicine at Queen’s University, said: “The local availability, speed and accuracy of the test will help inform public health preparedness and response in the ongoing pandemic.”
The test for COVID 19 disease utilises LAMP technology and Hibergene’s proprietary technology know how.
The Belfast Health & Social Care Trust carried out the initial development work on a prototype Meningococcal Disease test in collaboration with Queen's University Belfast and funded by the Meningitis Research Foundation and Health & Social Care Research and Development Division. The prototype technology was exclusively licenced by HSC Innovations to Hibergene Diagnostics Ltd, Dublin, Ireland, who subsequently commercialised the test for sale via Hibergene’s network of 45 Distributors covering over 70 countries worldwide.
Seamus Gorman, CEO of Hibergene said: “We are delighted to lead an international consortium to quickly develop and bring to market a rapid easy to use molecular diagnostic test for COVID 19 disease. Rapid diagnosis and reporting of results is the key to containing the COVID 19 disease and this test can play an important role in its diagnosis and control.”